Content area
Full Text
Eur J Clin Pharmacol (2012) 68:821832 DOI 10.1007/s00228-011-1184-3
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
Drug-induced immune thrombocytopaenia: results from the Berlin CaseControl Surveillance Study
Edeltraut Garbe & Frank Andersohn &
Elisabeth Bronder & Abdulgabar Salama &
Andreas Klimpel & Michael Thomae &
Hubert Schrezenmeier & Martin Hildebrandt &
Ernst Spth-Schwalbe & Andreas Grneisen &
Oliver Meyer & Hanife Kurtal
Received: 10 October 2011 /Accepted: 22 November 2011 /Published online: 21 December 2011 # Springer-Verlag 2011
AbstractPurpose Drug-induced immune thrombocytopaenia is a rare, serious condition that can be triggered by numerous medications. To characterize the spectrum of drugs associated with immune thrombocytopaenia (ITP) in the Berlin CaseControl Surveillance Study (FAKOS).
Methods Adult hospitalized patients with new onset idiopathic, secondary or drug-induced acute ITP and hospital control patients were ascertained by active surveillance in50 Berlin hospitals (>180 clinical departments) between 2000 and 2009. Drug exposures were obtained in a personal
interview. Chronic cases were excluded in a follow-up after 6 or more months. A standardized causality assessment was conducted for each ITP patient to assess possible drug aetiology. Drug risks were quantified in a casecontrol design with unconditional logistic regression analysis. Results Ninety out of 169 validated cases of acute ITP were assessed as being at least possibly drug-related (n085 different drugs overall, n030 drugs with certain or probable causality). Drugs involved in 2 cases with a probable or certain relationship were tirofiban (n010 cases), abciximab (n04), trimethoprim/sulphamethoxazole (n04), influenza
E. Garbe : E. Bronder : A. Klimpel : H. Kurtal Centre of Clinical Pharmacology and Toxicology, CharitUniversittsmedizin Berlin,Berlin, Germany
E. Garbe (*)
Bremen Institute for Prevention Research and Social Medicine, University of Bremen,Achterstrasse 30,28359 Bremen, Germanye-mail: [email protected]
F. AndersohnInstitute for Social Medicine, Epidemiology and Health Economy, CharitUniversittsmedizin Berlin,Berlin, Germany
A. Salama : O. MeyerInstitute for Transfusion Medicine, CharitUniversittsmedizin Berlin, Berlin, Germany
M. ThomaeDepartment of Surgery, Maria-Heimsuchung Caritas Klinik Pankow, Berlin, Germany
H. SchrezenmeierDRK Blood Transfusion Service Baden-WrttembergHessen, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm and University Hospital Ulm,Ulm, Germany
M. HildebrandtInterdisciplinary Centre of Cell Therapy, Technical University of Munich, Munich, Germany
E. Spth-Schwalbe Vivantes Klinikum Spandau, Berlin, Germany
A. GrneisenDepartment of Internal MedicineHaematology and Oncology, Vivantes Klinikum Neuklln,Berlin, Germany
822 Eur J Clin Pharmacol (2012) 68:821832
vaccine (n03), and citalopram (n02). Pneumococcal and poliomyelitis vaccine were assessed as...